Bank of America Corp DE boosted its position in shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) by 72

WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (

Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight

Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains

Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and mainta

Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.77) per share which missed the analys

- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date o

Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) and Arcturus Therapeutics (NASDAQ: ARCT - Get Free

WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (

Zenas BioPharma (ZBIO) is positioned as more than a rare-disease play, leveraging obexelimab's B-cel

CEO Leon Moulder acquired 60,000 shares for a total value of approximately $1.01 million on May 18,

WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (

US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results

WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma”

- The INDIGO study met its primary and all key secondary endpoints with statistically significant re

IgG4-RD is a debilitating chronic fibro-inflammatory disease affecting multiple organ systems, often

- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass. , May 28, 2026

INDIGO, the largest randomized, double-blind, placebo-controlled study conducted in IgG4-RD, met the

- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre,

WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (N

HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a

Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight

The ZB021 Phase 1 trial is supported by robust preclinical data demonstrating a desirable pharmacolo

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB0

Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.46) per share which missed the analys

– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA

Zenas BioPharma, Inc. maintains a Strong Buy rating, driven by obexelimab's positive phase 3 results

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”)

Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) shares rose 7.6% during trading on Thursday a

U.S. stocks down, NASDAQ drops 1.5% on Friday. Energy shares up, consumer discretionary down. Univer

U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu

Newsmax Inc (NMAX) shares rose on better-than-expected Q4 results & FY26 sales guidance. Pre-mar

Benzinga examined the prospects for many investors' favorite stocks over the last week — here&#3